Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.
Pitch Analysis
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
38%
Guest openness
Selective
Verified email on file
80/100
Required Score
Sign up to generate a grounded pitch for Medical Device Global Market Access.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Medical Device Global Market Access
UK MHRA Health Bill Amendments: Future of Medical Device Licensing
Sep 24, 20265 min
The UK government tabled three amendments to the Health Bill on September 1, 2026, signaling a major overhaul of the MHRA's regulatory powers for medical devices. This episode breaks down the proposals, including new information-sharing capabilities, measures for faster regulatory updates, and enabling powers for a potential future direct-to-regulator licensing system that could replace the current UK Approved Body model. We analyze the long-term strategic implications for manufacturers and outline practical steps for regulatory and quality teams to prepare for this evolving landscape. Key Questions: - What are the three major amendments to the UK Health Bill affecting the MHRA? - How will new information-sharing powers impact medical device manufacturers? - Why is the UK government seeking to make regulations more responsive to scientific changes? - What is the proposed future licensing regime for medical devices in the UK? - How could this new regime replace the current Approved Body conformity assessment model? - What was the significance of the September 1, 2026 date for these proposals? - What practical steps should regulatory teams take in response to this legislative development? - How does this potential shift align with other global regulatory models? Sources: - https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill How Pure Global can help: Navigating major legislative shifts like the proposed UK Health Bill amendments requires expert guidance and a forward-thinking strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Our services include regulatory strategy, continuous regulatory monitoring, and technical dossier preparation to help you anticipate and adapt to changes in over 30 markets. Let us help you maintain compliance and secure your market presence in a dynamic regulatory world. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
FDA's New PMA Electronic Submission Template: Draft Guidance Explained
Sep 23, 20265 min
This episode details the US FDA's new draft guidance on an electronic submission template for Premarket Approval (PMA) applications, issued on September 17, 2026. We explore which submission types are covered, such as Original PMAs and Panel-Track Supplements, and explain how the template aims to improve submission consistency and review efficiency for high-risk Class III medical devices. We also outline practical steps for regulatory and quality teams to prepare for this upcoming change. Key Questions: - What is the new FDA draft guidance on PMA electronic submissions issued in September 2026? - Which specific PMA submission types does the new template cover? - Why did the FDA introduce this standardized electronic template? - How will this new template impact the review process for high-risk devices? - What are the immediate next steps for regulatory teams preparing for a PMA submission? - Is the use of this new electronic template mandatory? - What are the potential benefits of adopting the template early? - How can manufacturers provide feedback on this draft guidance? Sources: - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-submission-template-premarket-approval-applications-pma - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates - https://www.govinfo.gov/content/pkg/FR-2026-09-18/html/2026-20202.htm How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We develop efficient regulatory strategies and use advanced AI to compile and manage technical dossiers for submissions to authorities like the FDA. Our team of local experts in over 30 countries can help you navigate complex requirements, ensuring your submissions are compliant and optimized for a smooth review. Whether you're a startup or a multinational, we can streamline your path to market. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global regulatory database at https://pureglobal.ai.
MFDS Korea Post-Market Study Exemption: Leveraging Overseas Data Under Notice 2026-63
Sep 22, 20266 min
This episode breaks down South Korea's Ministry of Food and Drug Safety (MFDS) Notice No. 2026-63, which details new evidence requirements for obtaining a post-market study exemption. Effective August 31, 2026, this notice affects manufacturers of new and orphan medical devices. We explain the specific criteria for demonstrating sufficient overseas use, including the required post-market clinical experience, safety information, and international sales history. This episode provides actionable guidance for regulatory and market access teams on how to leverage existing global data to meet these new standards and streamline entry into the Korean market. Key Questions: - What is MFDS Notice No. 2026-63 and who does it affect? - How can manufacturers of new or orphan medical devices gain an exemption from post-market studies in South Korea? - What specific types of overseas clinical experience data are now required? - What safety information, including recall and adverse event data, must be submitted? - How much international sales history is needed to satisfy the new MFDS criteria? - What are the practical steps for compiling a successful exemption application? - How does this change impact market access strategy for South Korea? Sources: - https://www.pure-global.com/insights/korea-mfds-2026-63-post-market-study-exemption-evidence/ - https://www.pure-global.com/news/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech companies navigate complex market access challenges like those in South Korea. Our experts can develop a clear regulatory strategy for your device, leveraging pathways like the post-market study exemption. We use advanced AI tools to efficiently compile, manage, and submit the technical dossiers required by authorities like the MFDS, ensuring your global clinical, safety, and sales data is presented effectively. For help with your Korean market access strategy or any of our 30+ markets, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.
Health Canada Exceptional Importation: Navigating the Updated Forms for Medical Device Shortages
Sep 21, 20264 min
This episode covers Health Canada's September 2, 2026, update to the forms for exceptional importation and sale of medical devices. We discuss the key changes, the criteria for using this pathway to address device shortages, and the practical steps manufacturers must take to prepare and submit successful applications. Key Questions: - What is Health Canada's exceptional importation pathway for medical devices? - What specific changes were made to the application forms on September 2, 2026? - How does a manufacturer prove a medical device shortage exists? - What information is now required to justify the need for a non-compliant device? - Who is eligible to apply for exceptional importation authorization? - What are the common pitfalls to avoid when submitting an application? - How can regulatory teams prepare for urgent shortage situations? - What is the long-term plan required for devices imported under this rule? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them access global markets faster. Our experts in Canada can guide you through complex pathways like the exceptional importation process, ensuring your submissions are comprehensive and meet Health Canada's clarified requirements. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative. By combining in-country expertise with advanced AI technology, we streamline compliance and help you maintain market presence. For support with your market access needs, contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
China NMPA GMP Inspection Guidance: Preparing for the November 1, 2026 Deadline
Sep 20, 20265 min
China's NMPA has released new mandatory GMP Inspection Guidance Principles, effective November 1, 2026. This episode breaks down the critical changes, including the new deficiency classification system (critical, major, and minor) and the impact on both production-license and post-market inspections. We provide practical, actionable steps for medical device manufacturers to conduct gap analyses, update internal audit programs, and prepare their quality systems for this more stringent regulatory environment to avoid enforcement actions and market access delays. Key Questions: - What are the key changes in China's new NMPA GMP Inspection Guidance Principles? - When does the new guidance become mandatory for all manufacturers? - How will NMPA inspectors classify deficiencies like critical, major, and minor findings after November 1, 2026? - What are the potential enforcement actions for non-compliance with the new GMP standards? - Which quality system areas are likely to face the most scrutiny during an inspection? - How can you conduct a gap analysis of your QMS against the new Chinese requirements? - What practical steps should your regulatory and quality teams take before the deadline? - Why is updating your internal audit program critical for NMPA inspection readiness? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFGPm-E4H7oXurZrQI5Z7_vIQsf33rHuKVY9zMYXA2miH_lOgvn1BzdYI0mV-APrMtGjiDgcTqVl3-6hts5MVvV0KL6fNawp255mdWxZdixxfdcUyGQN-zIXhC7kSuxau1iimCJvoNpiUTYxoQOqdohsAHpUnGzu6qVqEOepmljQs0vdSPnvPZHkmAHVXbS How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to enter or maintain their presence in global markets like China. Our experts can help you navigate the new NMPA GMP Inspection Guidance by developing a tailored regulatory strategy, conducting a thorough gap analysis of your QMS, and assisting with technical dossier preparation and submission. With local representation in over 30 countries, we ensure your company meets all local requirements efficiently. To learn how we can accelerate your market access, visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.
Every question we get asked before someone starts their trial.
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
What is the difference between Founder Solo and Founder Pro?
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
How do agency tiers work?
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
What is a talent profile?
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Can I switch plans later?
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Do you offer a free trial?
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
What happens if I cancel?
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Is the 20% annual discount automatic?
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
What if I have more than 50 profiles or 20 clients?
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
